BMO to Redeem $1,250 million Series J Medium-Term Notes (Non-Viability Contingent Capital (NVCC)) (Subordinated Indebtedness) Second Tranche Français
The redemption has been approved by the Office of the Superintendent of Financial Institutions. Notice will be delivered to holders of the Notes in accordance with the related indenture.
About BMO Financial Group
BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of January 31, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » NVO Total Return Level data by YCharts. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry 's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
6 hours ago
- Globe and Mail
UPS vs. Whirlpool: 2 High-Yield Stocks That Crashed, but Only one Is a Buy
Key Points Both UPS and Whirlpool's stocks are on multiyear downtrends, raising their yields. Whirlpool has cut its dividend in response, but UPS hasn't. However, UPS will likely feel a bigger negative impact from tariffs. 10 stocks we like better than United Parcel Service › Do you like bargain-priced stocks? How about bargain-priced dividend stocks? How about bargain-priced dividend stocks that you've actually heard of? Well, you're in luck! The stocks of two iconic American brands are currently sitting in the bargain bin. The companies are shipping behemoth UPS (NYSE: UPS) and appliance maker Whirlpool (NYSE: WHR). Both stocks have been slowly sinking for years, with share prices now down more than 60% from their all-time highs! Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Both stocks fell again -- by more than 15% -- after their recent second-quarter earnings reports, but one looks more likely to recover. Only one cut its dividend Both UPS and Whirlpool have long histories of paying and regularly increasing their dividends. By July, their share-price slumps had pushed both of their dividend yields above 7%. A yield that high is tempting, but neither company was on track to generate enough free cash flow to cover it. When a company can't cover its dividend with free cash flow, it has to dip into the cash on its balance sheet, take on additional debt, or find some other way to fund the payout. UPS is going to try to make it work somehow, according to CEO Carol Tome on the Q2 earnings call. She told investors, "You have our commitment to a stable and growing dividend." That means the company will be on the hook for at least $5.5 billion in dividend payouts this year, which seems almost certain to exceed its free cash flow for the year. That keeps UPS's yield high for now, but investors should remember that there's no guarantee the company's position won't change without warning, resulting in a surprise dividend cut. Whirlpool, on the other hand, cut its annual payout in half from $7 per share to $3.50 per share. That means its yield is now much lower than UPS's (4% vs. 7.5%), but its $190 million total payout is also much more manageable, making its dividend more sustainable over the long term. It also means the dividend cut is baked into the company's current share price, whereas if UPS makes a cut, its stock price will probably sink even lower in response. The ups and downs of tariffs UPS and Whirlpool are both bracing for the impact of tariffs, but in different ways. For UPS, the tariffs are a huge risk. They will likely cause imports to decline, resulting in lower shipping volumes. With some tariffs kicking in just as the labor market shows signs of weakness, they could negatively impact overall consumer spending (and thus, shipping) during the critical holiday shopping season. On the other hand, the tariffs may actually help Whirlpool by hurting its foreign competitors like LG, Samsung, and Haier. The Trump administration has proposed high tariffs on countries that happen to export lots of large appliances to the U.S. These include South Korea (25%), Thailand (36%), Vietnam (46%), and China (as high as 145%). Many of these rates are in flux, but even if they end up at 10% or 15%, it will still give Whirlpool, which manufactures more than 80% of its products in the U.S., a big pricing advantage. Although UPS's yield may now be higher than Whirlpool's, its prospects are looking dimmer thanks to economic factors outside of its control. Meanwhile, even after its dividend cut, Whirlpool still offers a decent yield and a compelling valuation. If I were to pick one, I'd go with Whirlpool hands down. Should you invest $1,000 in United Parcel Service right now? Before you buy stock in United Parcel Service, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and United Parcel Service wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
7 hours ago
- Globe and Mail
3 Tech Stocks That Could Go Parabolic
Key Points IonQ has the opportunity to be the big winner in quantum computing. SoundHound AI is looking to be a leader in voice and agentic AI. AppLovin has a huge opportunity to expand its AI adtech to areas other than gaming apps. 10 stocks we like better than IonQ › When it comes to investing, there are times when you're going to want to swing big. Not all these investments will pan out, but if one hits, your portfolio will greatly benefit. Just remember that these types of riskier picks should only account for part of an overall diversified portfolio. Let's look at three growth stocks that have the potential to go parabolic. 1. IonQ IonQ (NYSE: IONQ) is moving quantum computing from theory into the real world. The company is already delivering systems to commercial, government, and academic customers while working toward fault-tolerant machines that can run at scale. That's the breakthrough the industry needs to achieve mainstream success. IonQ is working from a position of strength. Following a recent equity offering, the company now has $1.6 billion in cash (as of July 9, 2025), making it one of the best-capitalized players in the field. In addition, the company is spending its money wisely by making key acquisitions to both expand its talent base and add new capabilities, such as space-based quantum networks. Its partnership with AstraZeneca, Amazon, and Nvidia, is working to demonstrate a quantum-accelerated computational chemistry workflow. This collaboration involves integrating IonQ's quantum processing unit with Nvidia's CUDA-Q platform, powered by Amazon's AWS infrastructure. It's showing early signs of success, with AstraZeneca seeing a 20-fold speed-up in drug development workflows. It has also recently formed a quantum networking division, making a move to become a leader in this space, as well. If quantum computing fulfills its promise, the market could be enormous. IonQ's combination of financial strength, key partnerships, and technology leadership puts it in a prime position to be one of the biggest winners in the space. 2. SoundHound AI SoundHound AI (NASDAQ: SOUN) is looking to carve out a leadership position in conversational and agentic artificial intelligence (AI). Its acquisition of Amelia last year gave it access to the company's advanced conversational intelligence, which it then combined with its "speech-to-meaning" and "deep meaning understanding" tech. The result is Amelia 7.0, a voice-first agentic AI platform that allows customers to create AI agents with little to no coding. These agents can complete tasks independently, which greatly expands the valuation proposition of SoundHound's platform. It's also added real-time AI visual recognition to its tech stack, making its platform even more powerful. SoundHound has long had a strong foothold in the automotive and restaurant sectors, where it continues to see strong success. Meanwhile, the Amelia acquisition gave it a solid foundation in other industry verticals, including financial services and healthcare, which are now major priorities. The strength of the combination was on full display in Q2, as SoundHound's revenue soared 217% year over year to $42.7 million, far outpacing expectations. It also raised its full-year guidance due to accelerating demand, and expects to reach adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability by the end of 2025. This is still an early-stage, high-risk investment, but the market potential for voice-powered and multimodal agentic AI is huge. If SoundHound can become a leader in this space, the stock has tremendous upside from here. 3. AppLovin AppLovin (NASDAQ: APP) has been one of the market's most explosive growth stories, with its shares up more than 400% over the past year. However, its outperformance could be far from done. Following the sale of its legacy gaming app portfolio, AppLovin is now a pure-play adtech platform. Its secret sauce is its AI engine, Axon 2.0, which optimizes ad targeting, bidding, and placement, driving strong results for its gaming app clients. It sees the gaming app market alone growing at a 20% to 30% annual pace for the foreseeable future. However, it has more growth drivers ahead. It's currently testing its platform with e-commerce and web-based ads, expanding beyond just gaming apps. It also plans to open its platform to advertisers outside the U.S. and launch a self-serve ads manager next year. Management believes this will be the foundation for its next leg of growth, expanding its customer base and use cases well beyond gaming. While short-sellers have taken shots at the company, AppLovin has continued to deliver strong revenue, earnings, and free cash flow growth quarter after quarter. If Axon 2.0 proves as effective outside gaming apps as it has within them, the stock could continue its vertical ascent. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, AppLovin, and Nvidia. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
